Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fausto Castagnetti

Showing results (61-70 of 158) with videos related to

Pageof 16
Sort By:
Journal of Clinical Epidemiology|June 21, 2020
Time to health-related quality of life improvement analysis was developed to enhance evaluation of modern anticancer therapiesFrancesco Cottone, Gary S Collins, Amelie Anota, et al.
Frontiers in Oncology|January 8, 2024
Metabolic pseudoprogression in a patient with metastatic KIT exon 11 GIST after 1 month of first-line imatinib: a case reportElisa Tassinari, Nicole Conci, Giacomo Battisti, et al.
Leukemia|May 18, 2021
Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational studyMassimo Breccia, Patrizia Pregno, Fausto Castagnetti, et al.
BMC Cancer|August 4, 2016
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutantsSimona Soverini, Caterina De Benedittis, Fausto Castagnetti, et al.
Haematologica|March 28, 2008
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcomeFrancesca Palandri, Ilaria Iacobucci, Fausto Castagnetti, et al.
Clinical and Translational Medicine|April 25, 2025
SETD2 loss of function is a recurrent event in advanced-phase chronic myeloid leukemia and contributes to genomic instability: SETD2 loss in Chronic Myeloid LeukemiaManuela Mancini, Sara De Santis, Cecilia Monaldi, et al.
Haematologica|January 19, 2007
Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working PartyGianantonio Rosti, Ilaria Iacobucci, Simona Bassi, et al.
British Journal of Haematology|February 8, 2017
Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcomeFederica Sora, Alessandra Iurlo, Simona Sica, et al.
Oncotarget|March 17, 2016
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patientsSimona Soverini, Caterina De Benedittis, Katerina Machova Polakova, et al.
Oncotarget|May 24, 2017
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cellsSimona Salati, Valentina Salvestrini, Chiara Carretta, et al.
Pageof 16

Showing results (61-70 of 158) with videos related to

Sort By:
Pageof 16
Journal of Clinical Epidemiology|June 21, 2020
Time to health-related quality of life improvement analysis was developed to enhance evaluation of modern anticancer therapiesFrancesco Cottone, Gary S Collins, Amelie Anota, et al.
Frontiers in Oncology|January 8, 2024
Metabolic pseudoprogression in a patient with metastatic KIT exon 11 GIST after 1 month of first-line imatinib: a case reportElisa Tassinari, Nicole Conci, Giacomo Battisti, et al.
Leukemia|May 18, 2021
Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational studyMassimo Breccia, Patrizia Pregno, Fausto Castagnetti, et al.
BMC Cancer|August 4, 2016
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutantsSimona Soverini, Caterina De Benedittis, Fausto Castagnetti, et al.
Haematologica|March 28, 2008
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcomeFrancesca Palandri, Ilaria Iacobucci, Fausto Castagnetti, et al.
Clinical and Translational Medicine|April 25, 2025
SETD2 loss of function is a recurrent event in advanced-phase chronic myeloid leukemia and contributes to genomic instability: SETD2 loss in Chronic Myeloid LeukemiaManuela Mancini, Sara De Santis, Cecilia Monaldi, et al.
Haematologica|January 19, 2007
Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working PartyGianantonio Rosti, Ilaria Iacobucci, Simona Bassi, et al.
British Journal of Haematology|February 8, 2017
Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcomeFederica Sora, Alessandra Iurlo, Simona Sica, et al.
Oncotarget|March 17, 2016
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patientsSimona Soverini, Caterina De Benedittis, Katerina Machova Polakova, et al.
Oncotarget|May 24, 2017
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cellsSimona Salati, Valentina Salvestrini, Chiara Carretta, et al.
Pageof 16